Clinical Trial Update: Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of melphalan, prednisone, thalidomide, and bortezomib in advanced and refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Melphalan (Melphalan)
• PREDNISONE (Prednisone)
• Thalidomide (thalidomide)

Snippet

Sponsor: University of Turin, Italy | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED